Nivolumab Induced Acute Pancreatitis and Hyperbilirubinemia

Immune checkpoint inhibitors (ICIs) are a novel treatment modality that is quickly becoming the standard of care for the management of a multitude of neoplasms. While immunomodulation is a promising approach, it also carries a risk of immune-related adverse effects (irAEs). Nivolumab is an FDA-approved anti-programmed death-1 (anti-PD-1) checkpoint inhibitor. Nivolumab-induced, immune-related pancreatitis, and hyperbilirubinemia are rare but clinically significant examples of irAEs. Early recognition and prompt management of these conditions are critically important to ensure a better prognosis and prevention of subsequent complications.